


For non-metastatic castration-resistant prostate cancer (nmCRPC),

adverse events are important to patients and caregivers when assessing risks versus benefits of treatment^{1,2}

Relative importance (%) of key attributes of nmCRPC treatment according to^{2*}:





In this relatively asymptomatic patient population, carefully balancing risks and benefits during treatment selection is important to optimise Quality of Survival

For nmCRPC patients,

Safety Counts



AE: adverse event; nmCRPC: non-metastatic castration-resistant prostate cancer

*Analysis of 143 non-metastatic castration-resistant prostate cancer patients and 149 caregivers; online discrete choice experiment survey of 14 questions, each comparing two hypothetical medication profiles varying in terms of five safety attributes (frequency or severity of AEs: fatigue, skin rash, cognitive problems, serious falls, and serious fractures) and two efficacy attributes (duration of overall survival and time to pain progression); percentages have been rounded up to the nearest 1%.

Reference: 1. Srinivas S, et al. J Clin Oncol. (2019). DOI: 10.1200/JCO.2019.37.27_suppl.196; **2.** Srinivas S, et al. Poster presented at the American Society of Clinical Oncology Quality Care Symposium, 2019. Available at: meetinglibrary.asco.org/record/179064/poster and bit.ly/3eQ4iF3.